Microparticle Immunocapture Assay for Protein Aggregate Sizing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to provide robust and accurate quantitative and qualitative analysis of pathological multimeric protein aggregates, lacking combination of target specificity, ease of use, speed of results, and availability of necessary instrumentation.
Innovation Solution
A method and assay using a capture substrate conjugated to a first capture moiety, followed by blocking and incubation with a test sample, then with a second capture moiety coupled to a signaling moiety for detectable label, allowing determination of the amount of detectable label on the substrate.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methods (electron microscopy, light scattering, electrophoresis, ELISA) are used to evaluate protein aggregation, then some aspect of protein aggregate analysis is achieved, but the methods fail to combine quantification of degree of aggregation with size of aggregates, target specificity, ease of use, speed of results, and availability of instrumentation
Solution Approach 1:
The patent merges multiple analysis capabilities into a single integrated assay system. The microparticle-based platform combines quantification of aggregation degree (via signal intensity) and size (via flow cytometry scatter properties) in one test, eliminating the need for multiple separate conventional methods while maintaining comprehensive measurement precision.
Solution Approach 2:
The microparticle assay platform provides multi-functionality by simultaneously enabling target specificity (through customizable capture moieties), ease of use (simple incubation protocol), speed of results (rapid signal development), and comprehensive measurement (aggregation degree and size) - all within a single instrument-compatible system.
2Measurement precision
If robust and accurate quantitative methods are developed to distinguish between protein monomers and aggregated multimers, then measurement precision is improved, but the methods lack ease of use and speed of results
Solution Approach 1:
The patent extracts the complex separation and identification task into a simplified microparticle-based capture system. By using microparticles with specific capture moieties that selectively bind to aggregate proteins, the method extracts the discrimination function from complex instrumentation and implements it through a simple incubation and detection protocol, greatly improving ease of operation.
Solution Approach 2:
The microparticle serves as an intermediary that mediates between the test sample and the detection system. The capture moieties on the microparticle surface provide a user-friendly interface for selective binding, while the signal development and flow cytometry analysis provide rapid, accurate distinction between monomers and aggregates without requiring complex sample preparation or specialized equipment operation.
3Measurement precision
If existing methods are used for protein aggregate detection, then some detection capability is achieved, but they lack target specificity and quantitative accuracy simultaneously
Solution Approach 1:
The patent segments the detection system into modular components: microparticles with customizable capture moieties for target specificity, flow cytometry for quantitative analysis, and signal development for detection. This segmentation allows the method to achieve both high target specificity (through customizable capture moieties) and quantitative accuracy (through flow cytometry) while maintaining versatility across different protein aggregates and disease models.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables quantitative and qualitative measurement of multimeric protein aggregates with high specificity and efficiency, suitable for clinical diagnostics and basic research on neurodegenerative diseases and pharmacologic preparations.
Implementation Method 1
the first capture moiety binds specifically to the aggregate protein if present, thereby forming a capture complex on the capture substrate
Implementation Method 2
a second capture moiety that specifically binds to the aggregated protein, wherein the second capture moiety is coupled to a signalling moiety, and wherein the signaling moiety comprises a detectable label
Data Source
AI summary
A number of protein aggregation diseases are associated with accumulation of misfolded proteins, which are known as protein aggregates, including, but not limited to, neurodegenerative and non-degenerative diseases and disorders. The present disclosure provides an assay, compositions and kits for the qualitative and quantitative assessment of aggregated proteins in solution using a microparticle immunocapture assay that combines the advantages inherent to a specific first and second capture moiety that binds specifically to an aggregated protein which can reveal at the same time the amount and the size of aggregates measured in a sample, fluid, tissue, cavity, or pharmacological product.